South America’s drug patent landscape isn’t “messy”—it’s strategic. And if you’re treating it like a single market, you’re likely missing the real story: the rules of exclusivity, enforcement, and pipeline protection vary dramatically country by countr…
South American Drug Patents: The Definitive Country-by-Country Breakdown Read Post »
Most 505(b)(2) strategies fail before the first filing—because teams treat it like a regulatory checkbox, not a business model.
If you’re a CDMO, specialty lab, or service provider supporting 505(b)(2) follow-on drugs, you’re not just helping sponsors …
Combining Lipitor (atorvastatin) with aspirin has been a topic of interest for healthcare professionals due to their common… https://www.Drugchatter.com/chat/18474/what-are-the-effects-of-combining-lipitor-and-aspirin/
DrugChatter: What are the effects of combining lipitor and aspirin? Read Post »
Pharma doesn’t always “block” generics with one big move. More often, it’s a layered strategy—stacking exclusivities, tweaking drug classifications, and extending market control long after the original patent cliff.
That’s the core story behind “Build …
India’s “drug patent clock” isn’t a clock at all—it’s a maze. Here’s how long protection really lasts.
If you’ve ever heard that a drug patent in India “lasts 20 years,” you’ve heard the headline—not the reality.
In practice, the effective protection w…
The generic drug race isn’t just about science—it’s about timing, leverage, and who wins the “first shot.”
If you’ve ever wondered why some generic launches feel like they happen overnight while others drag on for years, the answer is often hiding in…
Biopharma’s “Patent Cliff” Isn’t Just a Legal Event—it’s a Commercial Deadline.
If you’re in biopharma commercial, market access, or business development, you already know the headline: patents expire, generics and biosimilars arrive, and pricing press…
Biopharma is entering a new talent cycle—and the “next place” isn’t a lab, a clinic, or even a specific therapeutic area.
It’s the patent landscape.
A recent analysis from DrugPatentWatch on biosimilar patent wars makes a point that should be impossibl…
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next Read Post »
Specialty pharmacy contracts don’t wait for patents to expire. Neither should your strategy.
In biopharma, the most expensive mistake isn’t missing a launch date—it’s arriving too late to the commercial plumbing that determines whether patients actuall…
The internet keeps asking: “Can this drug do that?” The science answer is: sometimes—but the real story is how we learn.
Every day, someone somewhere posts a question that starts with a familiar phrase: “Can this drug do X?” A new study drops. A viral …
Can This Drug…Do That? The internet keeps asking. The pharmacology keeps sighing. Read Post »
Get new actionable insights and updates from BiotechBlog
